Growth factor release by activated platelets

Growth factor release by activated platelets is a physiological process where platelets secrete bioactive proteins from alpha-granules upon activation by agonists such as thrombin, collagen, or ADP [1]. These granules contain a diverse array of growth factors, including Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), and Vascular Endothelial Growth Factor (VEGF), which are essential for hemostasis, wound healing, and tissue repair [2, 3]. In pathological states, the excessive or chronic release of these factors contributes to the development of atherosclerosis, fibroproliferative diseases, and the "soil" for tumor metastasis [5]. Therapeutic strategies often involve antiplatelet drugs like aspirin or P2Y12 inhibitors (e.g., clopidogrel) that prevent platelet activation and the subsequent release of these growth factors to reduce cardiovascular risk [4]. Conversely, Platelet-Rich Plasma (PRP) therapy leverages this process to deliver high concentrations of growth factors directly to injured tissues to promote healing [3]. This process is a critical link between thrombosis and tissue remodeling, making it a focal point for both cardiovascular prevention and regenerative medicine.

Other names

Platelet degranulationPlatelet alpha-granule secretionRelease of platelet-derived growth factorsPlatelet-derived growth factor release

Drugs typically target the upstream activation of platelets to prevent the subsequent release of growth factors. This is achieved through the inhibition of cyclooxygenase-1 (COX-1), antagonism of P2Y12 ADP receptors, or blockade of protease-activated receptor-1 (PAR-1) and glycoprotein IIb/IIIa receptors [4].